- Home
- MPWR vs TAK Comparison
MPWR vs TAK Comparison
Compare MPWR & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MPWR | TAK |
|---|---|---|
| Founded | 1997 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.9B | 43.3B |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | MPWR | TAK |
|---|---|---|
| Price | $1,198.97 | $18.28 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 14 | 0 |
| Target Price | ★ $1,122.93 | N/A |
| AVG Volume (30 Days) | 709.7K | ★ 3.6M |
| Earning Date | 02-05-2026 | 01-29-2026 |
| Dividend Yield | 0.70% | ★ 2.92% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 12.75 | 0.45 |
| Revenue | $2,790,459,000.00 | ★ $28,475,252,603.00 |
| Revenue This Year | $18.80 | N/A |
| Revenue Next Year | $16.26 | $0.47 |
| P/E Ratio | $89.57 | ★ $40.27 |
| Revenue Growth | ★ 26.43 | N/A |
| 52 Week Low | $438.86 | $12.99 |
| 52 Week High | $1,250.00 | $18.16 |
Technical Indicators
Market Signals| Indicator | MPWR | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 62.08 | 79.09 |
| Support Level | $1,127.34 | $17.58 |
| Resistance Level | $1,250.00 | $17.99 |
| Average True Range (ATR) | 62.39 | 0.23 |
| MACD | 2.38 | 0.08 |
| Stochastic Oscillator | 73.30 | 99.56 |
Price Performance
Historical ComparisonAbout MPWR Monolithic Power Systems Inc.
Monolithic Power Systems is an analog and mixed-signal chipmaker specializing in power management solutions. Its mission is to reduce total energy consumption in end systems. It serves the computing, automotive, industrial, communications, and consumer end markets. MPS uses a fabless manufacturing model, partnering with third-party chip foundries to host its proprietary BCD process technology.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.